T he importance of angiotensin II (Ang II) in the development and maintenance of hypertension is well documented in several animal models of experimental hypertension, such as two-kidney, one-clip renal hypertension (2K1C), the Ren-2 gene transgenic rats, and the Ang IIinfused model. [1] [2] [3] [4] The Ang II-dependent increases in arterial blood pressure are commonly associated with higher levels of circulating and intrarenal Ang II levels, structural abnormalities, and functional derangements in the kidney. [1] [2] [3] [4] [5] [6] One important feature in the renin-angiotensin system profile observed in these rats is that renal Ang II levels are greater than can be explained on the basis of circulating Ang II and suppressed renin expression. 2, 4, [7] [8] [9] This suggests that angiotensin peptides continue to be generated intrarenally via a renin-independent pathway, or that circulating Ang II accumulates in one or more compartments within the kidney. 4, 9 Previous studies have shown that intrarenal Ang II levels are increased in the contralateral nonclip kidney of 2K1C hypertensive rats and in kidneys of Ang II-infused rats and Ren-2 transgenic rats. 2, 4, [7] [8] [9] Because blockade of the AT 1 receptor with losartan normalizes blood pressure and prevents augmentation of intrarenal Ang II levels, this enhanced uptake of Ang II within the kidney appears to be mediated by the AT 1 receptor. 9, 10 These results suggest that Ang II levels are augmented in intracellular compartments by an AT 1 receptormediated internalization mechanism and are protected from degradation to some extent.
Recent studies have localized angiotensin peptides in renal endosomes and intermicrovillar clefts, thus implicating them as potential sites for intracellular accumulation in the kid-ney. 11 Renal endosomes and intermicrovillar clefts from rat renal cortex also contain angiotensin converting enzyme (ACE) and AT 1 receptors. 11 In the present study, we first sought to determine whether intracellular accumulation of circulating or intrarenally formed Ang II into renal endosomes is increased during Ang II-dependent hypertension. Second, studies were performed to examine whether AT 1 receptor blockade with candesartan would prevent Ang II accumulation in whole kidney, renal endosomes, and intermicrovillar clefts. Third, flow cytometric analysis was used to measure AT 1 receptor antibody binding in renal intracellular endosomes isolated from normotensive and Ang II hypertensive rats. The present study demonstrates that during Ang II-induced hypertension, Ang II levels are markedly increased in parallel in the kidney, intermicrovillar clefts, and endosomes via an AT 1 receptor-mediated process.
Methods

Animal Preparation
Ang II-induced hypertensive rats were prepared as described previously. 4, 9, 10 Adult male Sprague-Dawley rats (Charles River Laboratories, Montreal, Quebec, Canada) were divided into three groups: Group 1 rats served as controls and did not receive any treatment (nϭ12); Group 2 rats received Ang II infusions at 80 ng/min via osmotic minipumps (nϭ12) (Alza Corporation) for 13 days; and Group 3 rats received concurrently Ang II infusion and the AT 1 receptor antagonist, candesartan, at 2 mg/kg/d for 13 days (nϭ8). Systolic blood pressures were monitored by tail-cuff plethysmography one day before and on Day 6 and Day 12, respectively, following Ang II or candesartan treatment. All experiments were approved by the Tulane University Animal Care and Use Committee.
Preparation of Plasma and Kidney Samples, Renal Endosomes, and Intermicrovillar Clefts
On Day 13 after initiation of the treatment, rats were decapitated and trunk blood samples collected for measurement of plasma renin activity (PRA) and Ang I and Ang II concentrations. 4,9 -11 Kidneys were immediately harvested, demedullated, and prepared separately for measurement of whole kidney Ang I and Ang II or for fractionation and purification of renal endosomes and intermicrovillar clefts as we described previously. 11, 12 Measurement of PRA and Circulating, Kidney, and Endosomal Ang II PRA was measured using a standard commercial kit (Incstar), and plasma and kidney Ang I and Ang II levels were determined by radioimmunoassay. 4,9 -11 Ang II levels in renal endosomes and intermicrovillar clefts were also determined by radioimmunoassay as we described previously 11 and expressed as femtomole per milligram (fmol/mg) endosomal protein. The sensitivity of Ang II immunoassays was Ϸ2 fmol, the specific binding was Ϸ41% and the nonspecific binding was Ϸ3%.
Flow Cytometric Analysis of Endosomal AT 1 Receptor Antibody Binding
AT 1 receptor antibody binding in renal endosomes and intermicrovillar clefts and its colocalization with entrapped marker fluorescein dextran were determined by flow cytometry as described previously. 11 Briefly, aliquots (25 L) of endosomal or intermicrovillar cleft vesicles were first preincubated in 50% goat serum for 2 hours at 22°C to reduce nonspecific binding and then incubated with serial dilutions of the AT 1A receptor antiserum at 4°C overnight. 11 After washing, endosomal samples were further incubated with 1:40 of goat anti-rabbit phycoerythrin-conjugated secondary antiserum for 4 hours at 22°C. The AT 1A receptor antibody binding tagged by phycoerythrin and fluorescein dextran were analyzed for each rat sample by a Becton-Dickinson FACSVantage flow cytometer using a dedicated Power Mac computer. 11, 12 
Data Analysis and Statistics
Data are presented as the meanϮSEM. The differences between different groups of animals in systolic blood pressure, PRA, plasma and kidney Ang I and Ang II, and endosomal Ang II levels were analyzed using one-way ANOVA followed by Dunnett's comparisons between groups' means. A value of PϽ0.05 was considered statistically significant.
An expanded Methods section can be found in an online data supplement available at http://www.hypertensionaha.org.
Results
Effect of Long-Term Ang II Infusion and/or Candesartan on Systolic Blood Pressure, PRA, and Plasma Ang I and Ang II Levels
Rats receiving chronic Ang II infusions developed hypertension by Day 6, which rose further by Day 12 (Table) . Concurrent administration of candesartan to Ang II-infused rats prevented the development of hypertension. Control rats remained normotensive throughout the duration of the experiment. PRA was markedly suppressed in Ang II-hypertensive rats, and conversely, it was elevated more than 6-fold in Ang II-infused rats treated concurrently with candesartan (Table) . Long-term Ang II infusion also significantly decreased plasma Ang I levels compared with controls (38Ϯ9 versus 70Ϯ9 fmol/mL). In contrast, plasma Ang II concentrations increased by almost 3-fold in Ang II-infused rats compared with controls. Concurrent administration of candesartan elevated PRA markedly and increased plasma Ang II levels further above the levels seen in rats receiving Ang II infusion alone (Table) . The increase in Ang II as a consequence of stimulation of PRA is presumably due to the blockade of the feedback inhibition of renin release by Ang II in the juxtaglomerular apparatus (JGA). 
Zhuo et al Ang II Accumulation in Rat Renal EndosomesEffects of Long-Term Ang II and/or Candesartan on Kidney and Endosomal Ang II Levels
Kidney Ang II levels in control rats averaged 186Ϯ26 fmol/g kidney weight and were increased to 399Ϯ39 fmol/g in Ang II-infused rats (PϽ0.05) (Figure 1 ). Unlike plasma Ang II levels, which increased further above the levels of Ang II-infused rats (Table) , kidney Ang II levels in candesartantreated Ang II-infused animals did not increase significantly from the levels observed in control rats (215Ϯ19 fmol/g kidney weight). Endosomal Ang II levels increased from 71Ϯ12 fmol/mg in control animals to 1100Ϯ283 fmol/mg endosomal protein in the Ang II-infused rats, whereas intermicrovillar cleft Ang II levels increased from 37Ϯ7 fmol/mg to 88Ϯ22 fmol/mg endosomal protein. Candesartan prevented the Ang II-induced increases in both endosomal and intermicrovillar Ang II levels ( Figure 1 ).
Effects of Long-Term Ang II Infusion on AT 1 Receptor Antibody Binding in Renal Endosomes and Intermicrovillar Clefts
To determine whether the increases in kidney, endosomal, and intermicrovillar Ang II levels in Ang II-infused rats are associated with alterations of AT 1 receptor expression, flow cytometry was employed to measure AT 1 receptor antibody binding in renal cortical endosomes. 11 Classic log concentration antibody binding curves were first determined to select the optimal concentration of AT 1 receptor antibody used for measurement of AT 1 receptor protein expression in renal endosomes and intermicrovillar clefts (not shown). As shown in Figure 2, 
Colocalization of Entrapped Endosomal Marker
Discussion
Internalization of the Ang II-AT 1 receptor complex following binding of the agonist to its membrane-bound receptors has been suggested to play an important role in mediating biological actions of Ang II in kidney cells. [13] [14] [15] Although fluorescence-labeled Ang II and AT 1 receptors have been localized in endosomes and/or lysosomes, the actual presence of internalized Ang II and AT 1 receptors in intracellular compartments has been reported only recently. 11 We demonstrated that rat renal cortical endosomes and intermicrovillar clefts contain detectable ACE, Ang I, Ang II, and AT 1 receptor, 11 therefore suggesting that the potential site(s) of intrarenal accumulation of circulating and intrarenally formed Ang II in Ang II-hypertensive rats are the intracellular endosomal compartments. In the present study, we observed marked increases in renal endosomal Ang II levels in rats receiving long-term Ang II infusion. This enhanced endosomal Ang II accumulation was associated with an increase in AT 1 receptor antibody binding in renal endosomes and intermicrovillar clefts and was prevented by the treatment of the Ang II-infused rats with the AT 1 receptor blocker, candesartan. Thus, our results confirm our hypothesis that Ang II levels are markedly elevated in renal intracellular endosomal compartments during Ang II-dependent hypertension.
To determine whether increased renal endosomal and intermicrovillar cleft Ang II levels were dependent on AT 1 receptor activation, an additional group of Ang II-infused rats was treated with the AT 1 receptor blocker, candesartan. We previously reported that losartan prevented intrarenal accumulation of infused exogenous Val 5 -Ang II in the kidney, indicating that intrarenal uptake of circulating Ang II is mediated by AT 1 receptors. 10 The results of the present study with candesartan demonstrate that AT 1 receptor blockade prevents the accumulation of Ang II in intracellular endosomal compartments. Indeed, blockade of AT 1 receptors with candesartan in Ang II-infused rats prevented not only the increase in whole kidney Ang II levels, but also the increases in endosomal and intermicrovillar cleft Ang II levels. These results support the hypothesis that increased intracellular accumulation of Ang II in renal endosomes during Ang II-induced hypertension is due to AT 1 receptor-mediated endocytosis and/or internalization. Internalization of Ang II via AT 1 receptors and blockade of Ang II internalization by losartan have been reported previously in cultured explantderived aortic vascular smooth muscle cells, 16 in the primary culture of bovine adrenal medullary chromaffin cells in vitro, 17 and in Chinese hamster ovary cells transfected with an AT 1a receptor linked to green fluorescent protein. 18 The above cited studies examined AT 1 receptor-Ang II complex internalization in isolated or cultured cells in vitro, but the content of internalized Ang II and AT 1 receptors in intracellular compartments was not determined. Our measurements of Ang II levels in renal intracellular endosomes and intermicrovillar clefts freshly isolated and purified from normotensive and Ang II-infused rats, and in rats treated concurrently with Ang II infusion and candesartan, serve as a direct in vivo corollary to the in vitro studies. The present findings provide direct evidence for increased Ang II accumulation in renal endosomes during Ang II-induced hypertension and for the important role of AT 1 receptors in mediating this process.
To ascertain whether enhanced intracellular trafficking of Ang II into renal endosomes is associated with increased expression of AT 1 receptors, we employed flow cytometry to quantify endosomal AT 1 receptors in normotensive and Ang II-infused rats. Using a rabbit anti-AT 1A receptor antibody that was raised against the cytosolic tail of the AT 1a receptor, 11 we detected significant increases in AT 1 receptor antibody binding in both endosomal and intermicrovillar clefts of Ang II-infused rats compared with their normotensive counterparts. These data demonstrate that increased endosomal Ang II levels in Ang II hypertensive rats are associated with increased AT 1 receptors in endosomes and intermicrovillar clefts. Upregulation of Ang II receptors or AT 1 receptors by Ang II has been documented previously in renal proximal tubules. 19, 20 Cheng et al 20 demonstrated that incubation of cultured rabbit proximal tubular cells with Ang II caused dose-dependent increases in both AT 1 receptor mRNA and specific 125 I-Ang II binding. Using quantitative in vitro autoradiography, Zhuo et al 19 recently reported that, in the Ren-2 gene transgenic hypertensive rat, AT 1 receptor binding in the cortical region corresponding to proximal tubules was increased in parallel with those in the glomeruli and the inner stripe of the outer medulla. Because these hypertensive rats exhibit high levels of circulating and intrarenal Ang II, 8, 19 these results suggest that proximal tubular AT 1 receptors are upregulated by ambient Ang II levels. Thus, our findings are consistent with the concept that increased expression of AT 1 receptors is responsible, at least in part, for enhanced Ang II accumulation in intracellular endosomal compartments during Ang II-dependent hypertension.
The physiological consequence of increased endosomal AT 1 receptor expression and enhanced intracellular accumulation of Ang II in renal endosomes during Ang II-dependent hypertension is yet to be determined. Accumulating evidence suggests that internalization of AT 1 receptors following binding of the agonist is not solely for the purpose of Ang II trafficking to the lysosomes for degradation and recycling of the receptors back to cell membranes. Rather, this process may be important for full expression of biological actions in different cells. 14, 15, 18, 21 A recent study showed that microinjection of Ang II directly into vascular smooth muscle cells induces an increase in intracellular calcium via an AT 1 receptor-mediated process. 22 In the kidney, endocytosis of the Ang II-AT 1 receptor complex increases phospholipase C and sodium flux and decreases cAMP in cultured proximal tubule epithelial cells following exposure to Ang II in vitro. 21, 23 Likewise, AT 1 receptor-mediated endocytosis of Ang II and increased recycling of AT 1 receptors have been linked to increased phospholipase A 2 activity and increased sodium flux in a tubule cell line expressing rabbit AT 1 receptors (LLC-PK). 24 Thus, increased internalization and/or accumulation of Ang II in renal endosomes may enhance proximal tubular sodium reabsorption and, therefore, contribute to the blunted pressure natriuresis relationship in Ang II-dependent hypertension. Chen et al 18 demonstrated Ang II-driven internalization of an AT 1 receptor-green fluorescent protein (AT 1 R-GFP) receptor complex and increased colocalization of the GFP fluorescence in nuclear regions. Long-term Ang II infusions have been shown to lead to increased angiotensinogen mRNA levels causing enhanced intrarenal production of angiotensinogen. 25, 26 Because of the evidence suggesting that the Ang II-AT 1 receptor complex may migrate to the nucleus, 18 it is possible that Ang IIdependent stimulation of angiotensinogen mRNA requires Ang II internalization and direct genomic action as proposed by Re. 27 Furthermore, increased accumulation of endosomal Ang II levels and AT 1 receptors may also play important roles in causing structural injury or derangements during Ang II hypertension. Intracellular Ang II may induce transforming growth factor-␤ or nuclear transcription factor-B expression to promote Ang II-induced tubulo-interstitial inflammation, 28 glomerulosclerosis, and renal microvascular hypertrophy. 3, 9 Overall, internalization of Ang II and AT 1 receptors into renal endosomes and intermicrovillar clefts may play important paracrine and intracrine roles in the hypertensinogenic and pathologic actions of Ang II on the kidney. 27 In summary, the present study demonstrates that during Ang II hypertension, Ang II levels are markedly increased in the kidney and in renal cortical endosomes and intermicrovillar clefts. These increases in endosomal and intermicrovillar cleft Ang II levels are associated with enhanced expression of AT 1 receptors in these intracellular compartments and are prevented by concurrent administration of AT 1 receptor blockers. These findings support the hypothesis that intrarenal trafficking/accumulation of angiotensin peptides into renal cortical tubular endosomes is enhanced during Ang II hypertension, and this process is mediated by AT 1 receptors. Thus, increased AT 1 receptor expression and internalization of Ang II-AT 1 receptor complex may be important for full expression of hypertensinogenic, paracrine, and intracrine actions of Ang II in the kidney during Ang II-dependent hypertension.
